The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 2.00 (0.89%)
Spread: 1.50 (0.662%)
Open: 228.00
High: 228.50
Low: 224.50
Prev. Close: 225.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

25 Jan 2024 07:00

RNS Number : 8282A
PureTech Health PLC
25 January 2024
 

25 January 2024

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

24 January 2024

Number of ordinary shares purchased:

35,192

Highest price paid per share:

198.00p

Lowest price paid per share:

192.80p

Volume weighted average price paid per share:

195.69p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 18,884,863 ordinary shares in treasury and has 270,583,296 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 270,583,296 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

24/01/2024

08:29:27

815

192.8

XLON

00386861372TRLO0.1.1

24/01/2024

08:29:44

315

192.8

CHIX

00386861432TRLO0.1.1

24/01/2024

08:29:44

213

192.8

CHIX

00386861433TRLO0.1.1

24/01/2024

08:29:59

815

192.8

XLON

00386861483TRLO0.1.1

24/01/2024

08:30:43

916

192.8

XLON

00386861719TRLO0.1.1

24/01/2024

08:31:31

622

192.8

XLON

00386862022TRLO0.1.1

24/01/2024

08:34:33

515

192.8

XLON

00386862779TRLO0.1.1

24/01/2024

08:34:33

13

192.8

XLON

00386862780TRLO0.1.1

24/01/2024

08:39:41

528

192.8

XLON

00386864131TRLO0.1.1

24/01/2024

08:44:47

528

192.8

XLON

00386865524TRLO0.1.1

24/01/2024

09:32:54

6336

195

XLON

00386876245TRLO0.1.1

24/01/2024

09:34:07

173

195

CHIX

00386876729TRLO0.1.1

24/01/2024

09:34:36

96

195

CHIX

00386876791TRLO0.1.1

24/01/2024

09:37:02

2112

195.4

XLON

00386877399TRLO0.1.1

24/01/2024

09:37:08

528

194.8

BATE

00386877491TRLO0.1.1

24/01/2024

09:37:08

528

194.8

CHIX

00386877492TRLO0.1.1

24/01/2024

09:37:08

283

194.8

AQXE

00386877493TRLO0.1.1

24/01/2024

09:58:58

528

197

XLON

00386882071TRLO0.1.1

24/01/2024

10:00:28

193

197

CHIX

00386882619TRLO0.1.1

24/01/2024

10:00:28

291

197.2

CHIX

00386882620TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884053TRLO0.1.1

24/01/2024

10:08:52

1584

196.8

XLON

00386884055TRLO0.1.1

24/01/2024

10:08:52

283

196.8

AQXE

00386884054TRLO0.1.1

24/01/2024

10:08:52

342

196.6

TRQX

00386884056TRLO0.1.1

24/01/2024

10:16:28

1056

196.6

XLON

00386885232TRLO0.1.1

24/01/2024

10:16:28

481

196.6

XLON

00386885233TRLO0.1.1

24/01/2024

10:39:12

35

196.4

CHIX

00386889783TRLO0.1.1

24/01/2024

10:39:12

493

196.4

CHIX

00386889784TRLO0.1.1

24/01/2024

10:39:12

388

196.4

CHIX

00386889785TRLO0.1.1

24/01/2024

10:39:12

528

196.4

XLON

00386889787TRLO0.1.1

24/01/2024

10:39:12

575

196.4

XLON

00386889786TRLO0.1.1

24/01/2024

10:39:12

231

196.4

XLON

00386889788TRLO0.1.1

24/01/2024

10:39:12

148

196.4

XLON

00386889789TRLO0.1.1

24/01/2024

10:39:12

176

196.4

XLON

00386889790TRLO0.1.1

24/01/2024

10:39:13

35

196

BATE

00386889793TRLO0.1.1

24/01/2024

11:13:47

2112

196.4

XLON

00386895560TRLO0.1.1

24/01/2024

11:14:55

119

196.2

CHIX

00386895706TRLO0.1.1

24/01/2024

11:34:12

579

196.4

CHIX

00386898389TRLO0.1.1

24/01/2024

11:34:12

528

196.4

BATE

00386898390TRLO0.1.1

24/01/2024

11:34:12

2085

196.4

XLON

00386898391TRLO0.1.1

24/01/2024

11:48:28

528

196.8

XLON

00386901072TRLO0.1.1

24/01/2024

11:50:46

409

196.2

BATE

00386901394TRLO0.1.1

24/01/2024

11:50:46

2112

196.4

XLON

00386901395TRLO0.1.1

24/01/2024

12:20:02

528

197

XLON

00386906123TRLO0.1.1

24/01/2024

14:44:34

283

198

AQXE

00386943011TRLO0.1.1

24/01/2024

14:44:34

287

198

CHIX

00386943012TRLO0.1.1

24/01/2024

14:46:50

500

198

XLON

00386945228TRLO0.1.1

24/01/2024

14:46:50

154

198

CHIX

00386945227TRLO0.1.1

24/01/2024

14:46:50

52

198

TRQX

00386945229TRLO0.1.1

24/01/2024

14:46:50

28

198

XLON

00386945230TRLO0.1.1

24/01/2024

14:46:50

199

198

TRQX

00386945231TRLO0.1.1

24/01/2024

14:46:50

119

198

TRQX

00386945232TRLO0.1.1

24/01/2024

14:46:50

472

198

XLON

00386945233TRLO0.1.1

24/01/2024

14:46:50

56

198

XLON

00386945234TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945235TRLO0.1.1

24/01/2024

14:46:50

528

198

XLON

00386945236TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTLIISFIS
Date   Source Headline
23rd May 20227:00 amRNSTransaction in Own Shares
20th May 20227:00 amRNSTransaction in Own Shares
19th May 20227:00 amRNSPDMR Notification RSU Vesting
19th May 20227:00 amRNSTransaction in Own Shares
18th May 20227:00 amRNSTransaction in Own Shares
17th May 202212:00 pmRNSPRTC to Present at UBS Healthcare Conference
17th May 20227:00 amRNSTransaction in Own Shares
16th May 20222:30 pmRNSPRTC Presents LYT-100 Data at ATS Conference
16th May 20227:00 amRNSTransaction in Own Shares
13th May 20227:00 amRNSTransaction in Own Shares
12th May 20227:00 amRNSTransaction in Own Shares
11th May 20227:00 amRNSTransaction in Own Shares
10th May 20227:00 amRNSTransaction in Own Shares
9th May 20227:00 amRNSPRTC Share Buyback Programme Commences Purchases
5th May 20227:00 amRNSPRTC Announces Share Buyback Programme Up to $50M
4th May 202211:35 amRNSGelesis Presents GS200 Weight Loss Data at ECO
3rd May 20227:00 amRNSTotal Voting Rights
29th Apr 202211:05 amRNSGelesis Data: Therapeutic Shows Gut Health Benefit
26th Apr 20227:00 amRNSPRTC Final Results & Publication of Annual Report
13th Apr 20224:44 pmRNSPRTC's Vedanta Publishes VE303 Data
12th Apr 202212:05 pmRNSAkili Depression Data Published in AJP
12th Apr 20227:00 amRNSGlyph: 20x Oral Bioavailability of Buprenorphine
7th Apr 20227:00 amRNSNotice of Results
1st Apr 20227:00 amRNSTotal Voting Rights
24th Mar 20227:00 amRNSPRTC Appoints Merck Vet to BOD & Audit Committee
17th Mar 20221:05 pmRNSAkili Adds Gaming Vet as Chief Product Officer
16th Mar 202210:35 amRNSGelesis: Record-Breaking Plenity Prescriptions
8th Mar 202212:05 pmRNSAkili Named to World's Most Innovative Companies
18th Feb 20224:30 pmRNSHolding(s) in Company
17th Feb 202212:05 pmRNSAkili Data: Enhanced Brain Activity in Kids w/ADHD
15th Feb 20227:00 amRNSPRTC's Akili Files Registration Statement on S-4
10th Feb 202212:00 pmRNSPRTC to Present at Leerink Healthcare Conference
4th Feb 20227:00 amRNSPDMR DEALING - PURCHASE OF SHARES
31st Jan 202211:50 amRNSPRTC's Gelesis Launches Plenity Media Campaign
26th Jan 202212:02 pmRNSPRTC’s Akili to Become Public & $162M Funding
14th Jan 20227:00 amRNSPRTC's Gelesis to Debut on NYSE Today Ticker GLS
7th Jan 202212:00 pmRNSPureTech to Present at JPM Healthcare Conference
6th Jan 20227:00 amRNSLYT-100 Shows Improved AE Profile vs Pirfenidone
5th Jan 202212:05 pmRNSGelesis Adds to BOD & Declared Effective by SEC
20th Dec 20217:00 amRNSPDMR DEALING - PURCHASE OF SHARES
16th Dec 20217:00 amRNSPRTC Provides Recap Ahead of Catalyst-Rich 2022
8th Dec 202112:00 pmRNSPRTC Presents Data at ACNP Conference For LYT-300
7th Dec 202112:00 pmRNSPRTC's Lymphatic Platform Candidate Human Study
1st Dec 202112:10 pmRNSPRTC: Gelesis' Plenity Now Broadly Available in US
1st Dec 20217:00 amRNSTotal Voting Rights
18th Nov 202112:10 pmRNSPRTC's Gelesis Receives $30M Plenity Order from Ro
16th Nov 202112:00 pmRNSPRTC Publishes Previous LYT-100 MAD Study Results
15th Nov 202112:00 pmRNSPRTC Presents at Two Upcoming Investor Conferences
12th Nov 202112:00 pmRNSPRTC Presents Immunooncology Ph 1/2 Trial at SITC
11th Nov 202112:00 pmRNSFDA Grants PRTC's LYT-200 Orphan Drug Designation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.